13F-HR filed by ACUTA CAPITAL PARTNERS, LLC
ACUTA CAPITAL PARTNERS, LLC filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 28 holding rows worth $96,768,753.
- Accession
- 0001104659-25-112378
- Filer
- CIK 1582844
- Filed
- 2025-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 28 entries on the cover page, a total value of $96,768,753 stated on the cover page (in dollars after the unit check, H1), rows summing to $96,768,753 with VALUE read as dollars as filed, 13F file number 028-16527. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 1,165,206 | $13,621,258 | dollars as filed | |
| CIDARA THERAPEUTICS INC | 171757206 | COM NEW | 141,529 | $13,552,817 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 268,451 | $12,840,011 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 3,410,402 | $6,479,764 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 38,592 | $5,557,634 | dollars as filed | |
| BRIGHT MINDS BIOSCIENCES INC | 10919W405 | COMMON STOCK | 84,875 | $5,148,518 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 6,379 | $4,704,895 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 333,258 | $4,528,976 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 502,797 | $3,776,005 | dollars as filed | |
| JAZZ PHARMACEUTICALS PLC SHS USD | G50871105 | Stock | 25,114 | $3,310,025 | dollars as filed | |
| COMPASS THERAPEUTICS INC | 20454B104 | COM | 840,090 | $2,940,315 | dollars as filed | |
| PRAXIS PRECISION MEDICINES I | 74006W207 | COM NEW | 49,751 | $2,636,803 | dollars as filed | |
| SURROZEN INC | 86889P208 | COMMON STOCK | 178,415 | $2,298,877 | dollars as filed | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 9,792 | $1,946,748 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 10,573 | $1,866,452 | dollars as filed | |
| OCULIS HOLDING AG | H5870P102 | CMN | 101,777 | $1,789,240 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 454,827 | $1,487,284 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 102,907 | $1,477,745 | dollars as filed | |
| ZYMEWORKS INC | 98985Y108 | COM | 80,143 | $1,368,842 | dollars as filed | |
| VERASTEM INC | 92337C203 | COMMON STOCK | 143,446 | $1,266,628 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 25,000 | $983,750 | dollars as filed | |
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 2,296 | $962,506 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 16,377 | $551,577 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 57,141 | $525,697 | dollars as filed | |
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 30,000 | $473,700 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 8,411 | $392,794 | dollars as filed | |
| UNICYCIVE THERAPEUTICS INC | 90466Y202 | COMMON STOCK | 59,985 | $261,535 | dollars as filed | |
| NUVATION BIO INC | 67080N119 | WARR | 90,832 | $18,357 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-25-112378 | this filing | 2025-11-14 | acceptance time not in the bulk data set |